Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials

作者全名："Zhang, Daojun; He, Guangqiao; Qian, Tian; Hao, Fei; Liu, Liwei"

作者地址："[Zhang, Daojun; He, Guangqiao; Qian, Tian; Hao, Fei] Chongqing Med Univ, Dept Skin Plast Surg & Beauty, Third Affiliated Hosp, Chongqing, Peoples R China; [Liu, Liwei] Chongqing Shapingba Dist Peoples Hosp, Chongqing, Peoples R China; [Liu, Liwei] Chongqing Shapingba Dist Peoples Hosp, 44 Xiaolongkan New St, Chongqing, Peoples R China"

通信作者："Liu, LW (通讯作者)，Chongqing Shapingba Dist Peoples Hosp, Chongqing, Peoples R China.; Liu, LW (通讯作者)，Chongqing Shapingba Dist Peoples Hosp, 44 Xiaolongkan New St, Chongqing, Peoples R China."

来源：POSTEPY DERMATOLOGII I ALERGOLOGII

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000891776500008

JCR分区：Q4

影响因子：1.4

年份：2022

卷号：39

期号：5

开始页：872

结束页：876

文献类型：Article

关键词：abrocitinib; atopic dermatitis; randomized controlled trials; meta-analysis

摘要："Introduction: The efficacy of abrocitinib for atopic dermatitis remains controversial. Aim: We conducted a systematic review and meta-analysis to explore the influence of abrocitinib versus placebo on the treatment of atopic dermatitis. Material and methods: We searched PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases up to June 2021 for randomized controlled trials (RCTs) assessing the effect of abrocitinib versus placebo for patients with atopic dermatitis. This meta-analysis was performed using a random-effect model. Results: Four RCTs involving 932 patients were included in the meta-analysis. Overall, compared with the control group for atopic dermatitis, abrocitinib has a remarkably positive impact on IGA response (OR = 6.60; 95% CI: 4.41-9.87; p < 0.00001), EASI-75 (OR = 9.19; 95% CI: 6.20-13.61; p < 0.00001), EASI-90 (OR = 10.50; 95% CI: 5.54-19.93; p < 0.0001), NRS response (OR = 6.99; 95% CI: 4.43-11.01; p < 0.00001) and adverse events (OR = 1.76; 95% CI: 1.23-2.52; p = 0.002), but showed no obvious influence on serious adverse events (OR = 0.53; 95% CI: 0.20-1.44; p = 0.22). Conclusions: Abrocitinib exerts a favorable effect on the treatment of atopic dermatitis."

基金机构：　

基金资助正文：